Last reviewed · How we verify
BHV-0223
At a glance
| Generic name | BHV-0223 |
|---|---|
| Also known as | sublingual riluzole |
| Sponsor | Biohaven Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS (PHASE1)
- Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder (PHASE2, PHASE3)
- Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |